Share Price and Basic Stock Data
Last Updated: January 24, 2026, 3:52 pm
| PEG Ratio | 4.77 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dr Lal Pathlabs Ltd operates in the Hospitals & Medical Services sector, with a current market price of ₹1,417 and a market capitalization of ₹23,752 Cr. The company reported total sales of ₹2,600 Cr for the trailing twelve months (TTM), reflecting a growth trajectory from ₹2,087 Cr in FY 2022 to ₹2,461 Cr in FY 2025. The quarterly sales figures also indicate a positive trend, with sales rising from ₹534 Cr in September 2022 to ₹601 Cr in September 2023. This upward momentum is further supported by a projected increase in sales to ₹660 Cr by September 2024, indicating a robust demand for the company’s services. The operating profit margin (OPM) stood at 31% as of the latest assessment, highlighting the company’s ability to maintain profitability amidst increasing operational costs. Overall, Dr Lal Pathlabs has demonstrated consistent revenue growth, positioning itself as a significant player in the Indian healthcare space.
Profitability and Efficiency Metrics
Dr Lal Pathlabs reported a net profit of ₹540 Cr for the TTM period, reflecting a substantial increase from ₹241 Cr in FY 2023. The company’s net profit margin was reported at 19.99% for FY 2025, indicating efficient management of expenses relative to revenues. The return on equity (ROE) stood at 24.3%, while the return on capital employed (ROCE) was 28.9%, both of which are favorable compared to typical industry benchmarks. The interest coverage ratio (ICR) was a robust 35.37x, suggesting that the company comfortably meets its interest obligations, which is particularly important given the low borrowings of ₹156 Cr. The cash conversion cycle remains impressively low at -110 days, indicating efficient operational management. Overall, the company showcases strong profitability metrics, reflecting effective cost control and operational efficiency.
Balance Sheet Strength and Financial Ratios
As of September 2025, Dr Lal Pathlabs reported total reserves of ₹2,304 Cr against borrowings of only ₹156 Cr, underscoring a strong balance sheet with minimal leverage. The total assets stood at ₹2,959 Cr, with fixed assets accounting for ₹1,232 Cr, indicating a solid investment in infrastructure. The company’s current ratio was notably high at 3.39, suggesting strong liquidity and the ability to cover short-term liabilities. The price-to-book value (P/BV) ratio was recorded at 9.53x, which is relatively high, suggesting that the stock may be priced at a premium compared to its book value. Additionally, the dividend payout ratio for FY 2025 was 41.03%, reflecting a commitment to returning value to shareholders while retaining sufficient earnings for future growth. These indicators reflect a well-capitalized entity with a strong financial foundation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dr Lal Pathlabs indicates a healthy distribution of ownership, with promoters holding 53.21% of the shares as of September 2025. Foreign institutional investors (FIIs) accounted for 21.86%, while domestic institutional investors (DIIs) held 18.22% of the total shares, reflecting strong institutional interest in the company. Public ownership stood at 6.07%, indicating a relatively stable shareholder base. Over the past year, promoter holdings have gradually decreased from 55.04% in December 2022, while FII participation has also seen a decline from 25.80%. This shift may reflect profit-taking or a reallocation of assets by institutional investors. Nonetheless, the substantial institutional ownership suggests confidence in the company’s long-term growth prospects. The number of shareholders decreased to 1,12,703, pointing towards a consolidation of ownership among more committed investors.
Outlook, Risks, and Final Insight
Looking ahead, Dr Lal Pathlabs is poised for continued growth, driven by its strong revenue performance and efficient operational metrics. However, potential risks include the declining trend in promoter and FII holdings, which could signal a lack of confidence or strategic repositioning. Additionally, the healthcare sector faces challenges related to regulatory changes and competition, which could impact profitability. The company’s low debt levels provide a buffer against economic downturns, but any significant operational disruptions could pose risks to its growth trajectory. Overall, if Dr Lal Pathlabs maintains its operational efficiency and addresses shareholder concerns, it is well-positioned to capitalize on the expanding healthcare market in India. The firm’s commitment to profitability and shareholder returns will play a crucial role in sustaining investor confidence moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.9 Cr. | 140 | 187/120 | 9.57 | 117 | 2.50 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 20.8 Cr. | 19.9 | 33.0/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.6 Cr. | 10.2 | 20.5/7.08 | 117 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 101 Cr. | 53.9 | 98.7/52.2 | 22.3 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.4 Cr. | 3.41 | 6.74/3.37 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,625.36 Cr | 653.48 | 85.41 | 93.18 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 534 | 489 | 491 | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 |
| Expenses | 390 | 376 | 375 | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 |
| Operating Profit | 144 | 113 | 116 | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 |
| OPM % | 27% | 23% | 24% | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% |
| Other Income | 9 | 10 | 14 | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 |
| Interest | 11 | 9 | 9 | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 |
| Depreciation | 39 | 38 | 38 | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 |
| Profit before tax | 103 | 76 | 83 | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 |
| Tax % | 30% | 30% | 32% | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% |
| Net Profit | 72 | 54 | 57 | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 |
| EPS in Rs | 4.30 | 3.17 | 3.40 | 4.95 | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.97 |
Last Updated: January 1, 2026, 10:04 pm
Below is a detailed analysis of the quarterly data for Dr Lal Pathlabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 731.00 Cr.. The value appears strong and on an upward trend. It has increased from 670.00 Cr. (Jun 2025) to 731.00 Cr., marking an increase of 61.00 Cr..
- For Expenses, as of Sep 2025, the value is 506.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 478.00 Cr. (Jun 2025) to 506.00 Cr., marking an increase of 28.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 224.00 Cr.. The value appears strong and on an upward trend. It has increased from 192.00 Cr. (Jun 2025) to 224.00 Cr., marking an increase of 32.00 Cr..
- For OPM %, as of Sep 2025, the value is 31.00%. The value appears strong and on an upward trend. It has increased from 29.00% (Jun 2025) to 31.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 25.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Jun 2025) to 25.00 Cr., marking a decrease of 3.00 Cr..
- For Interest, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 5.00 Cr..
- For Depreciation, as of Sep 2025, the value is 40.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Jun 2025) to 40.00 Cr., marking an increase of 5.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 204.00 Cr.. The value appears strong and on an upward trend. It has increased from 181.00 Cr. (Jun 2025) to 204.00 Cr., marking an increase of 23.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 25.00%, marking a decrease of 1.00%.
- For Net Profit, as of Sep 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 134.00 Cr. (Jun 2025) to 152.00 Cr., marking an increase of 18.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 8.97. The value appears strong and on an upward trend. It has increased from 7.90 (Jun 2025) to 8.97, marking an increase of 1.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 558 | 660 | 791 | 912 | 1,057 | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,227 | 2,461 | 2,600 |
| Expenses | 419 | 504 | 582 | 675 | 793 | 910 | 987 | 1,145 | 1,526 | 1,527 | 1,617 | 1,764 | 1,860 |
| Operating Profit | 139 | 156 | 210 | 238 | 264 | 294 | 344 | 436 | 561 | 490 | 609 | 698 | 739 |
| OPM % | 25% | 24% | 26% | 26% | 25% | 24% | 26% | 28% | 27% | 24% | 27% | 28% | 28% |
| Other Income | 8 | 12 | 20 | 27 | 31 | 46 | 55 | 51 | 52 | 42 | 69 | 91 | 104 |
| Interest | 0 | 0 | 0 | 1 | 1 | 1 | 15 | 16 | 30 | 38 | 29 | 22 | 20 |
| Depreciation | 27 | 28 | 28 | 28 | 33 | 38 | 73 | 77 | 108 | 150 | 144 | 142 | 147 |
| Profit before tax | 119 | 140 | 201 | 237 | 261 | 301 | 310 | 394 | 475 | 344 | 505 | 625 | 676 |
| Tax % | 33% | 31% | 34% | 34% | 34% | 33% | 27% | 25% | 26% | 30% | 28% | 21% | |
| Net Profit | 80 | 96 | 133 | 156 | 172 | 200 | 228 | 296 | 350 | 241 | 362 | 492 | 540 |
| EPS in Rs | 148.27 | 17.51 | 15.99 | 18.61 | 20.49 | 23.90 | 27.11 | 34.99 | 41.37 | 28.65 | 42.85 | 58.28 | 63.84 |
| Dividend Payout % | 7% | 9% | 15% | 16% | 22% | 25% | 44% | 57% | 29% | 42% | 56% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 20.00% | 38.54% | 17.29% | 10.26% | 16.28% | 14.00% | 29.82% | 18.24% | -31.14% | 50.21% | 35.91% |
| Change in YoY Net Profit Growth (%) | 0.00% | 18.54% | -21.25% | -7.04% | 6.02% | -2.28% | 15.82% | -11.58% | -49.39% | 81.35% | -14.30% |
Dr Lal Pathlabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 13% |
| 3 Years: | 6% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 17% |
| 3 Years: | 12% |
| TTM: | 35% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 11% |
| 1 Year: | -3% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 20% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 3:10 am
Balance Sheet
Last Updated: December 10, 2025, 2:36 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 54 | 55 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 |
| Reserves | 151 | 260 | 425 | 512 | 705 | 862 | 949 | 1,162 | 1,425 | 1,583 | 1,766 | 2,089 | 2,304 |
| Borrowings | 28 | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 533 | 420 | 247 | 157 | 156 |
| Other Liabilities | 119 | 134 | 118 | 95 | 128 | 145 | 341 | 415 | 309 | 297 | 357 | 383 | 415 |
| Total Liabilities | 352 | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,349 | 2,383 | 2,454 | 2,713 | 2,959 |
| Fixed Assets | 140 | 150 | 166 | 152 | 208 | 209 | 413 | 447 | 1,375 | 1,305 | 1,228 | 1,168 | 1,232 |
| CWIP | 0 | 1 | 4 | 18 | 10 | 3 | 11 | 10 | 15 | 5 | 6 | 3 | 17 |
| Investments | 9 | 38 | 64 | 106 | 145 | 185 | 164 | 59 | 65 | 150 | 114 | 327 | 486 |
| Other Assets | 203 | 286 | 391 | 414 | 554 | 694 | 786 | 1,144 | 893 | 923 | 1,107 | 1,215 | 1,225 |
| Total Assets | 352 | 475 | 625 | 690 | 916 | 1,091 | 1,374 | 1,661 | 2,349 | 2,383 | 2,454 | 2,713 | 2,959 |
Below is a detailed analysis of the balance sheet data for Dr Lal Pathlabs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 84.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 84.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,304.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,089.00 Cr. (Mar 2025) to 2,304.00 Cr., marking an increase of 215.00 Cr..
- For Borrowings, as of Sep 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 157.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 415.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 383.00 Cr. (Mar 2025) to 415.00 Cr., marking an increase of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,959.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,713.00 Cr. (Mar 2025) to 2,959.00 Cr., marking an increase of 246.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,232.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,168.00 Cr. (Mar 2025) to 1,232.00 Cr., marking an increase of 64.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 14.00 Cr..
- For Investments, as of Sep 2025, the value is 486.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Mar 2025) to 486.00 Cr., marking an increase of 159.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,225.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,215.00 Cr. (Mar 2025) to 1,225.00 Cr., marking an increase of 10.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,959.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,713.00 Cr. (Mar 2025) to 2,959.00 Cr., marking an increase of 246.00 Cr..
Notably, the Reserves (2,304.00 Cr.) exceed the Borrowings (156.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 111.00 | 129.00 | 210.00 | 238.00 | 264.00 | 294.00 | 344.00 | 436.00 | 28.00 | 70.00 | 362.00 | 541.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16 | 17 | 17 | 17 | 14 | 16 | 14 | 15 | 15 | 13 | 13 | 13 |
| Inventory Days | 37 | 31 | 33 | 44 | 40 | 70 | 39 | 38 | 28 | 30 | 27 | |
| Days Payable | 90 | 89 | 97 | 106 | 111 | 144 | 132 | 107 | 127 | 151 | 151 | |
| Cash Conversion Cycle | 16 | -35 | -42 | -47 | -47 | -55 | -60 | -78 | -54 | -87 | -108 | -110 |
| Working Capital Days | -26 | -9 | 27 | 19 | 17 | 0 | -19 | -17 | -54 | -56 | -46 | -30 |
| ROCE % | 60% | 48% | 47% | 43% | 38% | 35% | 32% | 33% | 29% | 18% | 25% | 29% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Flexi Cap Fund | 4,000,000 | 0.62 | 593.04 | 2,000,000 | 2026-01-26 06:37:47 | 100% |
| UTI Flexi Cap Fund | 2,401,252 | 1.43 | 356.01 | 1,200,626 | 2026-01-26 06:37:47 | 100% |
| Aditya Birla Sun Life Flexi Cap Fund | 1,668,560 | 0.99 | 247.38 | 823,007 | 2026-01-26 06:37:47 | 102.74% |
| Nippon India Multi Cap Fund | 1,302,307 | 0.38 | 193.08 | 417,494 | 2026-01-26 06:37:47 | 211.93% |
| SBI Large & Midcap Fund | 1,300,000 | 0.51 | 192.74 | 650,000 | 2026-01-26 06:37:47 | 100% |
| Nippon India Small Cap Fund | 1,290,970 | 0.28 | 191.4 | 645,485 | 2026-01-26 06:37:47 | 100% |
| Nippon India Pharma Fund | 1,218,224 | 2.19 | 180.61 | 609,112 | 2026-01-26 06:37:47 | 100% |
| HDFC ELSS Tax Saver Fund | 1,140,000 | 0.98 | 169.02 | 570,000 | 2026-01-26 06:37:47 | 100% |
| Sundaram Mid Cap Fund | 1,054,917 | 1.18 | 156.4 | 519,351 | 2026-01-26 06:37:47 | 103.12% |
| UTI Mid Cap Fund | 781,126 | 0.97 | 115.81 | 390,563 | 2026-01-26 06:37:47 | 100% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 58.48 | 43.05 | 28.82 | 41.70 | 35.33 |
| Diluted EPS (Rs.) | 58.40 | 42.98 | 28.74 | 41.70 | 35.25 |
| Cash EPS (Rs.) | 75.86 | 60.60 | 46.93 | 55.00 | 44.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 259.92 | 225.85 | 203.86 | 185.20 | 153.10 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 259.92 | 225.85 | 203.86 | 185.20 | 153.10 |
| Revenue From Operations / Share (Rs.) | 294.45 | 266.73 | 241.93 | 250.45 | 189.72 |
| PBDIT / Share (Rs.) | 94.39 | 81.27 | 63.76 | 73.58 | 58.51 |
| PBIT / Share (Rs.) | 77.41 | 64.06 | 45.74 | 60.61 | 49.24 |
| PBT / Share (Rs.) | 74.74 | 60.55 | 41.24 | 56.99 | 47.32 |
| Net Profit / Share (Rs.) | 58.89 | 43.40 | 28.92 | 42.03 | 35.57 |
| NP After MI And SOA / Share (Rs.) | 58.27 | 42.85 | 28.65 | 41.37 | 34.99 |
| PBDIT Margin (%) | 32.05 | 30.46 | 26.35 | 29.37 | 30.83 |
| PBIT Margin (%) | 26.29 | 24.01 | 18.90 | 24.20 | 25.95 |
| PBT Margin (%) | 25.38 | 22.70 | 17.04 | 22.75 | 24.94 |
| Net Profit Margin (%) | 19.99 | 16.27 | 11.95 | 16.78 | 18.74 |
| NP After MI And SOA Margin (%) | 19.79 | 16.06 | 11.84 | 16.51 | 18.44 |
| Return on Networth / Equity (%) | 22.42 | 19.34 | 14.33 | 22.86 | 23.42 |
| Return on Capital Employeed (%) | 27.95 | 26.86 | 19.90 | 27.25 | 29.58 |
| Return On Assets (%) | 17.93 | 14.56 | 10.01 | 14.65 | 17.55 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.05 | 0.11 | 0.00 |
| Total Debt / Equity (X) | 0.00 | 0.04 | 0.14 | 0.22 | 0.00 |
| Asset Turnover Ratio (%) | 0.95 | 0.91 | 0.85 | 0.96 | 1.01 |
| Current Ratio (X) | 3.39 | 2.42 | 2.07 | 1.75 | 4.18 |
| Quick Ratio (X) | 3.30 | 2.34 | 2.00 | 1.65 | 4.02 |
| Inventory Turnover Ratio (X) | 67.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 41.03 | 55.76 | 41.62 | 33.55 | 33.98 |
| Dividend Payout Ratio (CP) (%) | 31.77 | 39.78 | 25.55 | 25.54 | 26.87 |
| Earning Retention Ratio (%) | 58.97 | 44.24 | 58.38 | 66.45 | 66.02 |
| Cash Earning Retention Ratio (%) | 68.23 | 60.22 | 74.45 | 74.46 | 73.13 |
| Interest Coverage Ratio (X) | 35.37 | 23.11 | 14.16 | 20.32 | 30.47 |
| Interest Coverage Ratio (Post Tax) (X) | 23.07 | 13.34 | 7.42 | 12.61 | 19.53 |
| Enterprise Value (Cr.) | 19910.02 | 18177.25 | 14843.34 | 21493.23 | 21670.29 |
| EV / Net Operating Revenue (X) | 8.09 | 8.16 | 7.36 | 10.30 | 13.70 |
| EV / EBITDA (X) | 25.23 | 26.79 | 27.92 | 35.05 | 44.44 |
| MarketCap / Net Operating Revenue (X) | 8.42 | 8.48 | 7.56 | 10.41 | 14.27 |
| Retention Ratios (%) | 58.96 | 44.23 | 58.37 | 66.44 | 66.01 |
| Price / BV (X) | 9.53 | 10.21 | 9.15 | 14.41 | 18.12 |
| Price / Net Operating Revenue (X) | 8.42 | 8.48 | 7.56 | 10.41 | 14.27 |
| EarningsYield | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Dr Lal Pathlabs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 58.48. This value is within the healthy range. It has increased from 43.05 (Mar 24) to 58.48, marking an increase of 15.43.
- For Diluted EPS (Rs.), as of Mar 25, the value is 58.40. This value is within the healthy range. It has increased from 42.98 (Mar 24) to 58.40, marking an increase of 15.42.
- For Cash EPS (Rs.), as of Mar 25, the value is 75.86. This value is within the healthy range. It has increased from 60.60 (Mar 24) to 75.86, marking an increase of 15.26.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 259.92. It has increased from 225.85 (Mar 24) to 259.92, marking an increase of 34.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.45. It has increased from 266.73 (Mar 24) to 294.45, marking an increase of 27.72.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 94.39. This value is within the healthy range. It has increased from 81.27 (Mar 24) to 94.39, marking an increase of 13.12.
- For PBIT / Share (Rs.), as of Mar 25, the value is 77.41. This value is within the healthy range. It has increased from 64.06 (Mar 24) to 77.41, marking an increase of 13.35.
- For PBT / Share (Rs.), as of Mar 25, the value is 74.74. This value is within the healthy range. It has increased from 60.55 (Mar 24) to 74.74, marking an increase of 14.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 58.89. This value is within the healthy range. It has increased from 43.40 (Mar 24) to 58.89, marking an increase of 15.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 58.27. This value is within the healthy range. It has increased from 42.85 (Mar 24) to 58.27, marking an increase of 15.42.
- For PBDIT Margin (%), as of Mar 25, the value is 32.05. This value is within the healthy range. It has increased from 30.46 (Mar 24) to 32.05, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 26.29. This value exceeds the healthy maximum of 20. It has increased from 24.01 (Mar 24) to 26.29, marking an increase of 2.28.
- For PBT Margin (%), as of Mar 25, the value is 25.38. This value is within the healthy range. It has increased from 22.70 (Mar 24) to 25.38, marking an increase of 2.68.
- For Net Profit Margin (%), as of Mar 25, the value is 19.99. This value exceeds the healthy maximum of 10. It has increased from 16.27 (Mar 24) to 19.99, marking an increase of 3.72.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.79. This value is within the healthy range. It has increased from 16.06 (Mar 24) to 19.79, marking an increase of 3.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is 22.42. This value is within the healthy range. It has increased from 19.34 (Mar 24) to 22.42, marking an increase of 3.08.
- For Return on Capital Employeed (%), as of Mar 25, the value is 27.95. This value is within the healthy range. It has increased from 26.86 (Mar 24) to 27.95, marking an increase of 1.09.
- For Return On Assets (%), as of Mar 25, the value is 17.93. This value is within the healthy range. It has increased from 14.56 (Mar 24) to 17.93, marking an increase of 3.37.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.04 (Mar 24) to 0.00, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.95. It has increased from 0.91 (Mar 24) to 0.95, marking an increase of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 3.39. This value exceeds the healthy maximum of 3. It has increased from 2.42 (Mar 24) to 3.39, marking an increase of 0.97.
- For Quick Ratio (X), as of Mar 25, the value is 3.30. This value exceeds the healthy maximum of 2. It has increased from 2.34 (Mar 24) to 3.30, marking an increase of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 67.03. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 67.03, marking an increase of 67.03.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 41.03. This value is within the healthy range. It has decreased from 55.76 (Mar 24) to 41.03, marking a decrease of 14.73.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 31.77. This value is within the healthy range. It has decreased from 39.78 (Mar 24) to 31.77, marking a decrease of 8.01.
- For Earning Retention Ratio (%), as of Mar 25, the value is 58.97. This value is within the healthy range. It has increased from 44.24 (Mar 24) to 58.97, marking an increase of 14.73.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 68.23. This value is within the healthy range. It has increased from 60.22 (Mar 24) to 68.23, marking an increase of 8.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 35.37. This value is within the healthy range. It has increased from 23.11 (Mar 24) to 35.37, marking an increase of 12.26.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.07. This value is within the healthy range. It has increased from 13.34 (Mar 24) to 23.07, marking an increase of 9.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 19,910.02. It has increased from 18,177.25 (Mar 24) to 19,910.02, marking an increase of 1,732.77.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.09. This value exceeds the healthy maximum of 3. It has decreased from 8.16 (Mar 24) to 8.09, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.23. This value exceeds the healthy maximum of 15. It has decreased from 26.79 (Mar 24) to 25.23, marking a decrease of 1.56.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
- For Retention Ratios (%), as of Mar 25, the value is 58.96. This value is within the healthy range. It has increased from 44.23 (Mar 24) to 58.96, marking an increase of 14.73.
- For Price / BV (X), as of Mar 25, the value is 9.53. This value exceeds the healthy maximum of 3. It has decreased from 10.21 (Mar 24) to 9.53, marking a decrease of 0.68.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 8.42. This value exceeds the healthy maximum of 3. It has decreased from 8.48 (Mar 24) to 8.42, marking a decrease of 0.06.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lal Pathlabs Ltd:
- Net Profit Margin: 19.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 27.95% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 22.42% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.07
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.2 (Industry average Stock P/E: 85.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Block E, New Delhi Delhi 110085 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Brig.(Hony) Dr. Arvind Lal | Executive Chairman |
| Dr. Vandana Lal | Whole Time Director |
| Dr. Archana Lal Erdmann | Non Executive Director |
| Mr. Rahul Sharma | Non Executive Director |
| Mr. Arun Duggal | Independent Director |
| Mr. Gurinder Singh Kalra | Independent Director |
| Mr. Rajit Mehta | Independent Director |
| Mrs. Somya Satsangi | Independent Director |
| Mr. Rohit Bhasin | Independent Director |
FAQ
What is the intrinsic value of Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd's intrinsic value (as of 26 January 2026) is ₹1311.93 which is 4.66% lower the current market price of ₹1,376.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹23,062 Cr. market cap, FY2025-2026 high/low of ₹1,771/1,147, reserves of ₹2,304 Cr, and liabilities of ₹2,959 Cr.
What is the Market Cap of Dr Lal Pathlabs Ltd?
The Market Cap of Dr Lal Pathlabs Ltd is 23,062 Cr..
What is the current Stock Price of Dr Lal Pathlabs Ltd as on 26 January 2026?
The current stock price of Dr Lal Pathlabs Ltd as on 26 January 2026 is ₹1,376.
What is the High / Low of Dr Lal Pathlabs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dr Lal Pathlabs Ltd stocks is ₹1,771/1,147.
What is the Stock P/E of Dr Lal Pathlabs Ltd?
The Stock P/E of Dr Lal Pathlabs Ltd is 43.2.
What is the Book Value of Dr Lal Pathlabs Ltd?
The Book Value of Dr Lal Pathlabs Ltd is 142.
What is the Dividend Yield of Dr Lal Pathlabs Ltd?
The Dividend Yield of Dr Lal Pathlabs Ltd is 0.87 %.
What is the ROCE of Dr Lal Pathlabs Ltd?
The ROCE of Dr Lal Pathlabs Ltd is 28.9 %.
What is the ROE of Dr Lal Pathlabs Ltd?
The ROE of Dr Lal Pathlabs Ltd is 24.3 %.
What is the Face Value of Dr Lal Pathlabs Ltd?
The Face Value of Dr Lal Pathlabs Ltd is 10.0.